Sumitomo Pharma Co Ltd 2015 Annual Report with Sustainability Disclosures
The report presents Sumitomo Dainippon Pharma's operational and financial performance for fiscal 2014 (ended March 31, 2015). The Group recorded consolidated net sales of ¥371.4 billion and operating income of ¥23.3 billion, impacted by Japanese drug price revisions while benefiting from North American LATUDA® growth. Strategic R&D efforts focused on psychiatry, neurology, and oncology, including global Phase III trials. Environmental initiatives achieved a reduction in CO2 emissions to 72,981 tonnes, representing an 11% decrease compared to FY2005 levels.
Company: Sumitomo Pharma Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2015
Type: Annual Report with Sustainability Disclosures
Pages: 90
Back to company
Sumitomo Pharma Co Ltd
Annual Report
The report presents Sumitomo Dainippon Pharma's operational and financial performance for fiscal 2014 (ended March 31, 2015). The Group recorded consolidated net sales of ¥371.4 billion and operating income of ¥23.3 billion, impacted by Japanese drug price revisions while benefiting from North American LATUDA® growth. Strategic R&D efforts focused on psychiatry, neurology, and oncology, including global Phase III trials. Environmental initiatives achieved a reduction in CO2 emissions to 72,981 tonnes, representing an 11% decrease compared to FY2005 levels.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Apr 1, 2014 - Mar 31, 2015
Fiscal Year
2014
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management